term1 Definition1term2 Definition2term3 Definition3
Please sign in to your Google account to access your documents:
Varubi's indication
VARUBI is a substance P/neurokinkinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of Delayed nausea and vomiting associated with the initial and repeat causes entire of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Dose of Varubi
180mg rolapitant administered approximately 1 to 2 hours prior to the start of chemotherapy
Administer in combination with dexamethasone and a 5ht3 receptor antagonist
Section 12.1 of Varubi P.I.
Explain MOA of Varubi
Rolapitant is a selective & competitive antagonist of human substance P/NK1 receptors.
Rolapitant does not have significant affinity for NK2 or NK3 receptors or for a battery of other receptors, transporters, enzymes, and ion channels. Rolapitant is also active in animal models of chemotherapy -induced emesis.
Need help typing ? See our FAQ (opens in new window)
Please sign in to create this set. We'll bring you back here when you are done.
Discard Changes Sign in
Please sign in to add to folders.
Sign in
Don't have an account? Sign Up »
You have created 2 folders. Please upgrade to Cram Premium to create hundreds of folders!